23 results
Thumbnail

D2.283 - Beyond the skin. A rare case of contact angioedema due to Methylisothiazolinone

Thumbnail

D2.292 - Epinephrine Nasal Powder - a sustainable and reliable option for the treatment of anaphylaxis

Thumbnail

D2.293 - Assessment of the Efficacy of Specific Immunotherapy After a Long Break in Asthmatic Patients

Thumbnail

D2.278 - National Survey on Perioperative Hypersensitivity Reactions: Evaluating Practices and Challenges in Spanish Hospitals

Thumbnail

D2.279 - In an emergency, can YOU really give that adrenaline pen? – the need for structured, further and improved training in Ireland

Thumbnail

D2.282 - IgE-mediated anaphylaxis to quinine confirmed with a basophil activation test

Thumbnail

D2.284 - Eat the fruit, do not swallow the seed: A rare case of Cucurbitaceae allergy causing anaphylaxis

Thumbnail

D2.286 - A case of prawn induced FDEIA

Thumbnail

D2.287 - Evaluation of NSAID Hypersensitivity in Children: A Retrospective Analysis

Thumbnail

D2.288 - Idursulfase Hypersensitivity Reactions: Unpacking Immunological Mechanisms Beyond Clinical Manifestations

Thumbnail

D2.289 - A Cardiovascular Enigma in the Emergency Room

Thumbnail

D2.290 - Allergens involved in a case report of anaphylaxis to ginger (Zingiber officinale), a very rare but severe allergy

Thumbnail

D2.291 - The level of knowledge of adolescent and young adults about food allergies and anaphylaxis: Key information that can save lives - a pilot study

Thumbnail

D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab

Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates

Thumbnail

D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Thumbnail

D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results